Literature DB >> 116267

Maturational changes related to dopamine in the effects of d-amphetamine, cocaine, nicotine, and strychnine on seizure susceptibility.

C A Greer, H P Alpern.   

Abstract

The effects of four neural excitants (damphetamine, cocaine, nicotine, and strychnine) on myoclonic and clonic seizure susceptibility were investigated in two age groups (30 and 120 days) of short-sleep mice. Amphetamine and cocaine decreased susceptibility to myoclonus in young mice and increased susceptibility in mature mice. These effects were attenuated by pretreatment with haloperidol, indicating mediation by a dopaminergic system. Amphetamine did not alter clonic susceptibility in either age group of mice, whereas cocaine affected clonic susceptibility and myoclonus. These effects were not attenuated by haloperidol, indicating mediation by systems other than dopamine. Nicotine decreased susceptibility to myoclonus and increased susceptibility to clonus, whereas strychnine increased susceptibility to both types of seizure. Haloperidol, however, failed to alter any of these effects. These results are consistent with our previous work which suggests that a dopaminergic mechanism in these mice undergoes marked developmental changes between 30 and 120 days of age.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 116267     DOI: 10.1007/bf00427507

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  35 in total

1.  Mechanism of action of cocaine and amphetamine in the brain.

Authors:  J van ROSSUM; J van der SCHOOT; J A HURKMANS
Journal:  Experientia       Date:  1962-05-15

2.  Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data.

Authors:  A R Cools; J M Van Rossum
Journal:  Psychopharmacologia       Date:  1976-02-02

3.  Pre- and postsynaptic receptors in catecholaminergic transmission.

Authors:  K Starke; H D Taube; E Borowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977       Impact factor: 3.000

4.  Increased CNS sensitivity to flurothyl as a measure of physical dependence in mice following morphine, phenobarbital, and ethanol treatment.

Authors:  C A Greer; H P Alpern; A C Collins
Journal:  Life Sci       Date:  1976-06-15       Impact factor: 5.037

5.  The importance of endogenous catecholamines in the activity of some CNS stimulants.

Authors:  H H Wolf; D E Rollins; C R Rowland; T G Reigle
Journal:  Int J Neuropharmacol       Date:  1969-07

6.  Effects of nicotine on the release of 3 H-noradrenaline from the hypothalamus.

Authors:  G H Hall; D M Turner
Journal:  Biochem Pharmacol       Date:  1972-07-01       Impact factor: 5.858

7.  Lowered thresholds to flurothyl seizures after lateral geniculate lesions in rats.

Authors:  M W Adler
Journal:  Int J Neuropharmacol       Date:  1969-09

8.  Study on the excitation induced by amphetamine, cocaine and alpha-methyltryptamine.

Authors:  E Galambos; A K Pfeifer; L György; J Molnár
Journal:  Psychopharmacologia       Date:  1967

9.  Drug-induced catalepsy as influenced by convulsant and anticonvulsant drugs.

Authors:  G Zetler
Journal:  Neuropharmacology       Date:  1973-08       Impact factor: 5.250

10.  Paradoxical effects of amphetamine on preweanling and postweanling rats.

Authors:  B A Campbell; P J Randall
Journal:  Science       Date:  1977-03-04       Impact factor: 47.728

View more
  2 in total

1.  Evidence that the selectively bred long- and short-sleep mouse lines display common narcotic reactions to many depressants.

Authors:  H P Alpern; T D McIntyre
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 2.  Reinterpretation of the literature indicates differential sensitivities of long-sleep and short-sleep mice are not specific to alcohol.

Authors:  T D McIntyre; H P Alpern
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.